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Introduction: Metacognitions are considered to be crucial factors for the development
and maintenance of pathologic anxiety. The present case–control study aimed to
examine how metacognitive beliefs are associated with the diagnostic status and
subtypes of obsessive–compulsive disorder (OCD). In addition, we examined the pattern
of changes inmetacognitive beliefs after a 3-month pharmacological treatment in patients
with OCD.
Methods: A total of 562 cases with OCD and 236 healthy controls were assessed with
the Metacognitions Questionnaire (MCQ) and various measures of OC symptom severity.
Multivariate analyses of variance (MANOVAs) with covariates were conducted to explore
the relationship between subdimensions of metacognitive beliefs and OCD disease
status. In addition, for the OCD patients, Pearson’s correlation was performed between
baseline MCQ subdimensions and Obsessive–Compulsive Inventory-Revised-Korean
subscales (OCI-R-K). Finally, in a subset of drug-free OCD patients (n = 144), the MCQ
was reassessed after 3 months of treatment and patterns of changes in subdimensions
of the MCQ were examined.
Results: Patients with OCD scored significantly higher on the four dimensions
of the MCQ. There were significant associations between all MCQ subdimensions
and OCI-R-K subscales. In the repeated-measure MANOVA, a significant group
(non-responders vs. responders)-by-time interaction effect was found only for the
negative beliefs about the uncontrollability and danger of worry (NB) subdimension
(F = 10.75; η2 = 0.072; p = 0.001).
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Conclusion: The presence of dysfunctional metacognitive beliefs in OCD subjects and
their association with OCD characteristics suggest that dysfunctional metacognitions
may play a crucial role in the pathophysiology of OCD. Improvement of metacognitive
beliefs in the NB dimension may be a clinically meaningful correlate of good treatment
response in the pharmacological treatment of OCD.
Keywords: dysfunctional metacognitive beliefs, metacognition, negative beliefs about worry, OCD, treatment
response
INTRODUCTION
Obsessive–compulsive disorder (OCD) is a debilitating
psychiatric disorder characterized by obsessions, which are
intrusive thoughts and images that increase anxiety, and
compulsions, which are repetitive or ritualistic actions to
decrease anxiety (1). Metacognition, the knowledge or beliefs
about thinking and strategies used to control thinking processes,
has been suggested to play an important role in the maintenance
of such symptoms (2). The first metacognitive model of OCD
proposed by Wells assumes that beliefs about the importance
of thinking cause a person to assign high significance to his/her
thoughts, and when that person experiences an obsession,
metacognitive processing is activated, which accesses knowledge
about the intrusion (3). The metacognitive model of OCD
has been validated with empirical studies. In a study of 238
University students, thought-fusion beliefs, beliefs about the
need to perform rituals, and criteria that signal rituals can
be stopped explained the variance in obsessive–compulsive
symptoms in the theorized causal sequence (4). In another study
of 304 community volunteers, thought-fusion beliefs and beliefs
about rituals predicted obsessive-compulsive symptoms, further
providing empirical support for the metacognitive model (5).
In addition, metacognitive therapy (MCT), which specifically
focuses on metacognition, has also been developed and has
shown promising results (6). In a study of 25 OCD patients,
after 15 weekly sessions of MCT, 74% of patients met the criteria
for recovery (7). In another study that compared MCT to OCD
CBT, 95 OCD patients who participated in 12 weekly sessions of
MCT improved significantly more than the CBT cohort; 86.3%
of patients in the MCT group responded compared with 64% in
the CBT group (8).
There has been a series of studies that examined the
relationship between metacognition and OC symptoms in the
general population. In a study of 120 undergraduate students,
there was a positive association between metacognitive factors
and OC symptoms (2). In another study of 110 undergraduate
students, metacognitions as measured by the Metacognitions
Questionnaire (MCQ) were significant predictors of OC
symptoms such as symmetry and unacceptable thoughts (9).
Finally, in a study of 305 community volunteers, metacognitive
beliefs were found to be related to obsessive–compulsive behavior
such as washing and checking (10).
Although the relationship between metacognition and OCD
has been extensively studied on a conceptual level, there is still
a lack of clinical data regarding the subject matter. There are a
few studies involving OCD patients, but they have been limited
by small sample size, with most studies involving fewer than
100 OCD patients. In a study of 114 OCD patients using the
MCQ, OCD patients scored significantly higher than controls
on two dimensions: negative beliefs about worry concerning
uncontrollability and danger, and beliefs about the need to
control thoughts (11). Similarly, in a study of 117 subjects
(52 OCD patients and 65 healthy controls) and a study of 97
subjects (51 OCD patients and 46 healthy controls), the same
two sub-dimensions of the MCQ were elevated in OCD patients
compared to controls (12). In a study of 75 OCD patients, OCD
patients reported significantly more positive beliefs about rituals
and stop signals than did the patients with anxiety disorder,
patients with depressive disorder, and non-clinical controls (13).
Finally, in a study of 51 OCD patients and 46 controls, negative
beliefs about worry concerning uncontrollability and danger were
shown to be significantly higher inOCDpatients (14). In addition
to the small sample size mentioned above, some studies were
also uncontrolled for depression and anxiety, which are known
to affect metacognition (12).
There is also a lack of studies that examined the change in
metacognition in OCD patients as they receive treatment. In one
of those studies, Solem et al. (15) followed 83 OCD patients
who received 12 weekly sessions of exposure and response
prevention (ERP). After ERP, there was a significant decrease in
the Y-BOCS and MCQ scores, and regression analysis showed
that a change in metacognition explained 22% of the variance
in OCD symptoms (15). To our knowledge, no study has
observed changes in metacognition in OCD patients receiving
pharmacological treatment. In our prior study of 132 OCD
patients, the metacognition subdimension of positive beliefs
about worry at baseline was a significant predictor of early
symptom improvement after 1 month of pharmacotherapy, but
metacognition was not measured repeatedly (16).
The present study aimed to examine how metacognitive
beliefs are associated with the diagnostic status and subtypes of
OCD and OCD-related characteristics. In addition, we examined
the pattern of changes in the subdimensions of metacognitive
beliefs according to treatment response by assessing the
metacognitive beliefs at baseline and repeating the measurement
following 3 months of pharmacological treatment.
METHODS
Participants
A total of 562 OCD patients and 236 controls were recruited
from the outpatient clinic of Severance Hospital in Seoul, Korea,
through consecutive screening and enrollment from 2010 to
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2020. All participants were assessed using the Structured Clinical
Interview for DSM-IV Axis I disorders (SCID-I) by trained
psychiatrists. Of the 562 OCD patients, 144 patients were drug-
naïve or drug-free of any psychiatric medication for at least 3
months prior to participation. These patients were started on
pharmacological treatment depending on the clinical decision of
a psychiatrist who was independent from the rater and statistical
analyst in this study. All participants provided written informed
consent prior to the beginning of this study. The study protocol
was approved by the Institutional Review Board of Severance
Hospital, and all methods of this study were carried out in
accordance with the approved guidelines. The IRB approval
numbers were 4-2010-0577 and 4-2015-0655.
Assessment
At baseline, all participants were asked to answer standardized
questions on social-demographic characteristics including age,
sex, year of education, marital status, occupation, average
monthly income, height/weight, age of OCD onset (for
patients only), and psychiatric medication. All controls were
never diagnosed with psychiatric illness and were drug-
naïve. At baseline, all participants were also asked to answer
the following standardized questionnaires: the Yale–Brown
Obsessive Compulsive Scale (Y-BOCS), Montgomery–Asberg
Depression Rating Scale (MADRS), and Obsessive–Compulsive
Inventory-Revised-Korean (OCI-R-K). Tomeasure each patient’s
metacognitive beliefs, the MCQ was completed.
The 144 drug-free patients who started on pharmacological
treatment were again assessed after 3 months. At the 3-month
follow-up, the participants completed the same questionnaires
that they completed at baseline.
CLINICAL CHARACTERISTICS
Yale–Brown Obsessive Compulsive Scale
To evaluate the severity of obsessive–compulsive disorder
symptoms, the Y-BOCS was administered to OCD patients at
baseline and at 3-month follow-up. The Y-BOCS is a 10-item
scale, and each item is scored on a scale ranging from 0 to 4, with
higher scores indicating higher symptom severity (17).
Obsessive-Compulsive
Inventory-Revised-Korean
The OCI-R-K is another scale that evaluates the severity of
obsessive–compulsive disorder symptoms (18). It is an 18-item
scale, and each item is scored on a scale ranging from 0 to 4, with
higher scores indicating higher symptom severity. It comprises
six subscales of OCD symptoms: washing, checking, ordering,
obsessing, hoarding, and neutralizing.
Montgomery–Asberg Depression Rating
Scale
To evaluate the severity of depressive symptoms, the MADRS
was administered to both cases and controls at baseline and at
the 3-month follow-up. MADRS is a 10-item scale, and each
item is scored on a scale ranging from 0 to 6, with higher scores
indicating higher depressive symptom severity (19).
METACOGNITIVE BELIEFS
Metacognitions Questionnaire
The MCQ was developed to measure beliefs about worry and
intrusions (20). It is composed of 65 questions, which are scored
on a four-point scale ranging from 1 (“Do not agree”) to 4
(“Agree very much”). The MCQ is composed of five subscales:
positive beliefs about worrying (PB), negative beliefs about the
uncontrollability and danger of worry (NB), beliefs about the
need for control of thoughts (NFC), beliefs concerning cognitive
competence (CC), and cognitive self-consciousness (CSC). The
MCQ was administered to both cases and controls at baseline,
and to cases at the 3-month follow-up.
Statistical Analysis
Statistical analysis was conducted using Statistical Package
for the Social Sciences version 25.0 (SPSS Inc., Chicago, IL,
USA). Missing value analysis was performed using the SPSS
expectation-maximization (EM) algorithm. The EM imputation
provides unbiased parameter estimates when data are missing
completely at random and a very small portion of data are
missing (21). Subjects were excluded from the analysis if missing
data exceeded 5% of the total number of items, andmissing values
below 5% were imputed using the EM estimates. Independent
sample t-test and chi-square test were performed to compare the
demographic information between OCD patients and controls.
Multivariate analysis of variance (MANOVA) was performed
to compare baseline MCQ scores between OCD patients and
controls, while controlling for age, sex, and MADRS. For OCD
patients, Pearson’s correlation was performed to observe the
correlation of baseline MCQ subdimensions with OCI-R-K
subscales and the Y-BOCS. For OCD patients who were followed
up after 3 months, repeated measures ANOVA was performed,
controlling for age, sex, and MADRS; treatment response was set
as the between-subjects factor and time was set as the within-
subjects factor, to test for the difference in MCQ subdimension
scores between baseline and follow-up. Response was defined as
a ≥35% reduction in the Y-BOCS at follow-up (22).
RESULTS
Demographic and Clinical Characteristics
The demographic and clinical characteristics of the patients are
presented in Table 1. There was no difference in age, sex, or
duration of education between OCD patients and controls, but
OCD patients scored significantly higher on the Y-BOCS [25.52
(7.01) vs. 0.47 (1.86), p < 0.001] and MADRS [20.45 (9.64)
vs. 3.39 (4.09), p < 0.001] compared to controls. All patients
on follow-up were taking serotonin reuptake inhibitors (SRIs),
including escitalopram (n= 108), and some of them were taking
concomitant medications including benzodiazepines (n = 44)
and atypical antipsychotics (n= 26).
Comparison of MCQ Scores Between
Patients and Controls
The comparison of MCQ scores between OCD patients and
controls are presented inTable 2.When uncontrolled, there was a
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TABLE 1 | Demographic and clinical characteristics of participants.
OCD (n = 562) Control (n = 236) p
Age (years) 28.12 (8.25) 27.47 (8.14) 0.521
Sex, male, % 61.03% 58.05% 0.432
Education (years) 13.78 (2.35) 13.95 (2.20) 0.151
Y-BOCS 25.52 (7.01) 0.47 (1.86) <0.001
Onset of illness (years) 18.12 (7.66) NA NA
Duration of illness (years) 10.92 (8.49) NA NA
MADRS 20.45 (9.64) 3.39 (4.09) <0.001
The means (standard deviations) are given for age, education, Y-BOCS, Onset of illness,
Duration of illness, and MADRS.
OCD, obsessive compulsive disorder; MADRS, Montgomery–Åsberg Depression Rating
Scale; Y-BOCS, Yale–Brown Obsessive Compulsive Scale.
P-values in bold are significant at α < 0.05.
significant difference in the NB (p< 0.001), NFC (p< 0.001), CC
(p< 0.001), and CSC (p< 0.001) subdimensions, as well as in the
total MCQ score (p < 0.001). When the analysis was controlled
for age, sex, andMADRS, the results were similar as there was still
a significant difference in NB (p < 0.001), NFC (p = 0.003), CC
(p < 0.001), and CSC (p= 0.001) subdimensions as well as in the
total MCQ score (p< 0.001) between OCD patients and controls.
Correlation Between MCQ, OCI-R-K, and
Y-BOCS Scores
The correlations between the MCQ subdimensions, OCI-R-K
subscales, and Y-BOCS scores are presented in Table 3. There
were significant associations between all MCQ subdimensions
and OCI-R-K subscales.
MCQ Score at the 3-Month Follow-Up
At follow-up, 48 patients (33.3%) showed≥35% reduction in the
Y-BOCS and were classified as responders, and 96 (66.7%) were
non-responders. The Y-BOCS and MADRS scores of the patients
on follow-up are presented in Table 4. The analysis revealed
a statistically significant group-by-time interaction for the NB
subdimension (F = 10.75; η2p = 0.072; p= 0.001) and total MCQ
score (F = 5.364; η2p = 0.037; p = 0.022) controlling for age,
sex, and MADRS (Figure 1, Table 4). There was no significant
group-by-time interaction effect for other MCQ subdimensions,
and there was no main effect of time (Table 4).
DISCUSSION
In the present study, we adopted both a cross-sectional and
a prospective perspective to examine the role of dysfunctional
metacognitive beliefs in OCD. The results showed that compared
to healthy controls, OCD patients scored significantly higher
on subdimensions of negative beliefs about the uncontrollability
and danger of worry (NB), beliefs about the need for control
of thoughts (NFC), cognitive self-consciousness (CSC), and
beliefs concerning cognitive competence (CC). In addition, when
changes in metacognitive beliefs were observed prospectively
as the patients received pharmacological treatment, there was
a significant group (responders vs. non-responders)-by-time
interaction effect in the NB subdimension. The results indicate
that certain subdimensions of metacognition may play a crucial
role in the pathophysiology and clinical course of OCD.
Our comparisons of metacognitive beliefs between OCD
patients and healthy controls at a cross-sectional level revealed
that OCD patients scored higher on the subdimensions of NB,
NFC, CSC, and CC, in both uncontrolled and controlled analyses.
Moreover, in the correlational analysis, these four dimensions
were associated with all of the OCD symptom dimensions.
Notably, NB was the subdimension with the largest difference
between patients and controls. This result is consistent with
findings shown in previous reports of OCD with smaller samples
using theMCQ30, a shorter version of the original MCQ (12, 14).
In one study, the authors found NB to be the most successful
subdimension in differentiating individuals with OCD from
controls. In addition, regarding the other subdimensions (NFC,
CSC, and CC), although the results have been inconsistent in
previous studies with smaller sample sizes (12, 14), our study
found that NFC, CSC, and CC were all significantly elevated
in patients with OCD. It is possible that prior studies might
have been underpowered to detect the actual differences in those
dimensions. High metacognitive beliefs in specific dimensions,
such as negative beliefs about the uncontrollability of thoughts
and danger, which relate to the perceived dangerousness of
thoughts (e.g., “Worrying is dangerous for me”) and beliefs about
need to control thought (e.g., “I should be in control of my
thoughts all of the time”), may contribute to the excessive effort of
suppressing normally occurring intrusive thoughts by perceiving
them as uncontrollable and dangerous and thus converting them
into significant, unwanted obsessions and pathologic rituals.
This explanation can be supported by Wegner’s Ironic Process
Theory of mental control, which posits that attempts to suppress
intrusive thoughts are counterproductive as shown in the “white
bear” study of the paradoxical effect of thought suppression
(23). In a meta-analytic review of dysfunctional metacognition in
different mental disorders, NB and NFC showed the largest effect
sizes out of the five MCQ subdimensions (Hedges’ g = 1.5417
and 1.643, respectively) when comparing OCD patients to
controls (24).
In addition, our prospective results showed that there was a
significant interaction effect of time and group (responders vs.
non-responders) only for the subdimension of NB following 3
months of pharmacological treatment. This finding indicates that
at least early on in the course of pharmacotherapy, a decrease
in NB is associated with an improvement in OC symptoms.
These results also imply that metacognitive therapies that target
negative beliefs about the uncontrollability and danger of worry
may be helpful in controlling OC symptoms in OCD patients.
Further studies are needed to confirm which subdimensions of
metacognition change according to time and treatment.
Notably, the subdimension of PB showed a different
pattern from other subdimensions. While PB was not
associated with OCD status in the between-group analysis,
the pattern of association with OCD symptom dimensions
was different for PB than for other MCQ subdimensions.
For the ordering symptom dimension (which corresponds
to symmetry/order-related obsessions and compulsions), PB
showed the strongest association out of all MCQ subdimensions,
while for the obsessing symptom dimension [which corresponds
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TABLE 2 | Comparison of MCQ scores between patients and controls.
MCQ OCD (n = 562) Control (n = 236) Uncontrolled Controlled for age, sex, MADRS
t p F η2p p
PB 37.67 (11.28) 36.94 (9.01) −0.97 0.333 1.65 0.002 0.200
NB 46.53 (11.65) 25.78 (7.21) −30.52 <0.001 155.99 0.176 <0.001
NFC 20.23 (6.40) 14.64 (4.33) −14.30 <0.001 9.12 0.012 0.003
CC 31.72 (8.24) 21.02 (4.78) −22.92 <0.001 56.67 0.072 <0.001
CSC 20.44 (4.52) 17.12 (3.74) −10.75 <0.001 11.47 0.015 0.001
Total 156.59 (31.47) 115.45 (21.27) −21.41 <0.001 45.04 0.068 <0.001
Pillai’s trace = 0.67; F = 296.78; p < 0.001. MCQ, metacognitions questionnaire; OCD, obsessive compulsive disorder; MADRS, Montgomery–Åsberg Depression Rating Scale; PB,
positive beliefs about worry; NB, negative beliefs about the uncontrollability and danger of worry; NFC, beliefs about the need for control of thoughts; CC, beliefs concerning cognitive
competence; CSC, cognitive self-consciousness.
P-values in bold are significant at α < 0.05.
TABLE 3 | Correlation between MCQ subdimensions, OCI-R-K subscales, and Y-BOCS scores.
MCQ Hoarding Washing Checking Neutralizing Ordering Obsessing Total YBOCS
PB 0.224** 0.160** 0.261** 0.273** 0.302** 0.164** 0.331** 0.104*
NB 0.259** 0.090* 0.259** 0.243** 0.153** 0.543** 0.358** 0.234**
NFC 0.280** 0.170** 0.248** 0.217** 0.207** 0.398** 0.344** 0.229**
CC 0.343** 0.144** 0.216** 0.323** 0.236** 0.516** 0.407** 0.168**
CSC 0.276** 0.113** 0.293** 0.206** 0.240** 0.399** 0.374** 0.185**
Total 0.363** 0.179** 0.339** 0.347** 0.304** 0.533** 0.482** 0.241**
*p< 0.01, **p< 0.001, MCQ, metacognitions questionnaire; PB, positive beliefs about worry; NB, negative beliefs about the uncontrollability and danger of worry; NFC, beliefs about the
need for control of thoughts; CC, beliefs concerning cognitive competence; CSC, cognitive self-consciousness; Y-BOCS, Yale–Brown Obsessive Compulsive Scale; OCI-R-K, Obsessive
Compulsive Inventory-Revised-Korean.
Pearson’s correlation coefficient larger than 0.3 is presented in bold.
TABLE 4 | MCQ scores at baseline and follow-up.
MCQ Baseline Follow-up (3 months) Factor time Factor group Time x group interaction
Non-responders Responders Non-responders Responders F P F P F P
PB 37.18 ± 11.34 37.50 ± 10.78 40.70 ± 12.80 39.37 ± 11.22 0.345 0.558 0.020 0.887 1.076 0.302
NB 46.39 ± 12.29 44.81 ± 11.44 43.98 ± 11.25 36.28 ± 11.78 0.020 0.889 3.938 0.049 10.757 0.001
NFC 20.46 ± 6.42 18.49 ± 5.49 20.95 ± 6.57 18.32 ± 5.49 3.373 0.068 4.157 0.043 0.546 0.461
CC 31.69 ± 8.84 29.12 ± 6.68 30.52 ± 8.65 26.89 ± 8.47 0.185 0.667 3.277 0.072 0.974 0.325
CSC 20.25 ± 4.97 19.47 ± 4.28 20.46 ± 4.43 18.28 ± 3.39 0.000 0.988 2.421 0.122 3.308 0.071
Total 156.48 ± 34.06 150.06 ± 26.23 156.54 ± 33.62 139.34 ± 30.50 0.131 0.718 3.53 0.062 5.364 0.022
Y-BOCS 27.18 ± 5.37 28.71 ± 6.11 25.04 ± 5.36 13.19 ± 5.04
NA
MADRS 19.76 ± 9.17 21.09 ± 8.06 18.17 ± 9.12 8.88 ± 6.36
Pillai’s trace = 0.63; F = 45.97; p < 0.001. MCQ, metacognitions questionnaire; PB, positive beliefs about worry; NB, negative beliefs about the uncontrollability and danger of worry;
NFC, beliefs about the need for control of thoughts; CC, beliefs concerning cognitive competence; CSC, cognitive self-consciousness; Y-BOCS, Yale-Brown Obsessive Compulsive
Scale; MADRS, Montgomery-Asberg Depression Rating Scale.
P-values in bold are significant at α < 0.05.
to sexual/religious (forbidden/taboo) thoughts], it showed the
weakest association. In our preliminary report, OCD patients
with higher PB baseline scores were associated with poorer
outcomes in terms of early improvement after 1 month of
pharmacotherapy (16). Although the role of PB in OCD has
not been extensively studied, it has been examined in other
psychiatric disorders. In a study that examined metacognitive
beliefs in people with psychotic disorders, positive beliefs
about psychotic symptoms (e.g., suspiciousness is good and
keeps an individual safe) were suggested to contribute to more
frequent and severe psychotic symptoms (25). In a study that
examined the role of metacognition in depression, the results
suggest that positive metacognitive beliefs may serve as a
trigger for the application of rumination as an incompatible
coping mechanism for depression (26). These findings suggest
that PB is a subdimension that works as a psychological trait
that affects the disease course by reinforcing maladaptive
coping with the psychopathology of OCD by considering
compulsive behavior such as arranging and organizing as safe and
protective rituals.
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FIGURE 1 | Negative beliefs about the uncontrollability and danger of worry at follow-up.
There are some study limitations that should be noted. First,
the follow-up period was only 3 months, which may not be
enough to observe response or remission, since OCD is a chronic
condition. Although 3 months may be a suitable period for
follow-up in the short term because patients with OCD typically
take 10–12 weeks to respond to SRIs (27), future longitudinal
studies with more than 1 year of follow-up are needed to see
how certain subdimensions of metacognition change as OCD
patients are treated with pharmacotherapy. Studies with longer
follow-up will also be helpful in observing whether the change
in metacognition is permanent or only temporary. Second, we
did not consider other measures of cognitive function such as
working memory capacity, which may affect metacognition (28).
Third, because the subjects of our study were OCD patients
who were referred to university hospitals, most of the patients
showed severe OC symptoms, which may not be representative
of OCD patients in general. Fourth, we did not control for
the different types of psychiatric medication that the drug-
naïve patients started taking from baseline; different psychiatric
medications may affect OC symptom severity differently. Fifth,
some of the scales used in this study including the MCQ
are self-reported, and self-report may produce answers that
are exaggerated and affected by various biases such as social
desirability bias. Sixth, we did not control for other clinical
characteristics such as comorbid Axis II personality disorder,
which could affect treatment response (29). Finally, we did not
include any OCD-specific measure of metacognition. While the
MCQ is a reliable and valid measure of metacognitions, it is not
an OCD-specific measure (20).
In conclusion, this study showed that compared to healthy
controls, metacognitive subdimensions of NB, NFC, CC, and
CSC were elevated in OCD patients, and when the patients are
treated over time, a decrease in certain dimensions, specifically
NB, was observed in responders, but not in non-responders.
Understanding specific metacognitive difficulties and tailoring
metacognitive interventions could be helpful in enhancing
symptom improvement and treatment response for patients with
OCD. Future longitudinal studies with longer follow-up are
needed to establish how metacognitive beliefs are involved in
the pathophysiology of OCD and how certain metacognitive
subdimensions change in the long term as OC symptoms
are treated.
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